The research team, led by investigators including Deep Goswami and Mitali Chatterjee, analyzed skin biopsies and blood plasma from PKDL patients and compared them with samples from healthy controls. Using immunohistochemistry and immunofluorescence, they quantified the populations of immune cells infiltrating the lesions, including CD8-positive T cells, CD68-positive macrophages, CD20-positive B cells, and CD66b-positive neutrophils. In parallel, they measured the levels of chemokines and cytokines circulating in the plasma using multiplex assays and ELISA, and examined the integrity of key structural proteins in the skin, such as E-cadherin, intercellular adhesion molecule-1, fibronectin, collagen types I and IV, and laminin.

What they found was a coordinated immune invasion. PKDL lesions were densely infiltrated with immune cells, and the hierarchy was clear: monocytes and macrophages dominated, followed by CD8-positive T cells, then neutrophils, and finally B cells. This was not a random accumulation but a targeted recruitment. The researchers detected elevated levels of specific chemokines in the circulation, including CCL2, CCL3, CCL4, CCL5, CXCL9, CXCL10, and IL-8, and these chemokines positively correlated with the abundance of their corresponding immune cell populations in the tissue. In other words, the chemical signals in the blood were acting as homing beacons, drawing each immune cell type into the skin lesions where they accumulated.

The structural consequences of this infiltration were equally striking. E-cadherin, a molecule that glues keratinocytes together and helps maintain the integrity of the epidermis, was significantly downregulated in the lesions, with the most pronounced reduction seen in macular lesions, the flat, pale patches characteristic of the disease. Meanwhile, intercellular adhesion molecule-1, or ICAM-1, was elevated, reflecting the inflammatory activation of the tissue. The extracellular matrix, the protein scaffold that gives skin its shape and resilience, was also significantly depleted, with reduced levels of fibronectin, collagen I, collagen IV, and laminin across both macular and polymorphic forms of PKDL.

Critically, the loss of these structural components was not independent of the immune invasion. The researchers found that the depletion of extracellular matrix proteins correlated inversely with the degree of immune cell infiltration, meaning that the more immune cells crowded into a lesion, the more the underlying scaffold was eroded. This inverse relationship suggests that the immune cells, or the inflammatory molecules they produce, are actively breaking down the tissue architecture rather than simply occupying space left behind by other processes.

To identify the molecular culprits, the team turned to the enzymes and cytokines known to degrade structural proteins. Matrix metalloproteinase 9, or MMP9, an enzyme capable of cleaving collagen and other matrix components, was elevated in the lesions. So were the pro-inflammatory cytokines TNF-alpha and IFN-gamma. Importantly, the levels of these molecules correlated inversely with E-cadherin and the extracellular matrix proteins, providing a plausible mechanism: the inflammatory milieu, rich in TNF-alpha, IFN-gamma, and MMP9, drives the breakdown of the adhesion molecules and structural proteins that hold the skin together.

The systemic picture reinforced the local one. In the plasma of PKDL patients, pro-inflammatory cytokines including TNF-alpha, IFN-gamma, IL-6, and IL-1beta were elevated, along with IL-4, a cytokine more typically associated with allergic and humoral immune responses. This combination suggests that PKDL is not a purely Th1 or Th2 inflammatory state but a mixed immune environment in which multiple signaling pathways converge on the skin. The elevated circulating chemokines, which correlated with tissue infiltration, further support the idea that the blood is carrying the instructions for immune cell homing to the lesions.

The clinical significance of these findings lies in their potential to explain the most visible and stigmatizing feature of PKDL: hypopigmentation. The researchers propose that the loss of E-cadherin and extracellular matrix components, driven by MMP9, TNF-alpha, and IFN-gamma, could cause a site-specific loss of melanocytes, the pigment-producing cells of the skin. If the structural framework that supports melanocytes is dismantled, those cells may be lost or dysfunctionally displaced, resulting in the pale patches that characterize macular PKDL. This mechanism links the immune pathology directly to the visible symptom, a connection that had remained poorly defined until now.

Beyond the mechanistic insight, the study has implications for how PKDL might be monitored and treated. The correlation between circulating chemokines and tissue infiltration suggests that blood markers could serve as non-invasive indicators of disease activity, potentially reducing the need for repeated skin biopsies. The identification of TNF-alpha, IFN-gamma, and MMP9 as central drivers of tissue remodeling also points to potential therapeutic targets. If the enzymatic and cytokine-mediated breakdown of E-cadherin and the extracellular matrix can be modulated, it may be possible to preserve skin architecture and prevent or reverse the hypopigmentation that causes so much social and psychological burden for patients.

PKDL remains a significant public health challenge in regions where visceral leishmaniasis is endemic, particularly in the Indian subcontinent and East Africa. Because PKDL patients can harbor parasites in their skin, they are thought to act as reservoirs that sustain transmission even after large-scale treatment campaigns have reduced visceral disease. Understanding the immune-mediated remodeling of skin architecture in PKDL therefore serves a dual purpose: it illuminates the biology of a neglected disease and may contribute to strategies aimed at interrupting the transmission cycle. By revealing how chemokine-driven immune infiltration, cytokine-mediated inflammation, and matrix-degrading enzymes converge to dismantle the skin’s structural integrity, this study provides a foundation for developing interventions that could improve both the clinical management and the epidemiological control of this disfiguring sequela of kala-azar.

Subject of Research: Immune-mediated tissue remodeling and hypopigmentation in Post-Kala-Azar Dermal Leishmaniasis

Article Title: Immune-mediated remodelling of tissue architecture in Post-Kala-Azar Dermal Leishmaniasis (PKDL)

Article References: Goswami, D., Saha, S., Roy, M., Mohammad, E., Maji, R., Sengupta, R., Sengupta, S., Roy, S., Chaudhuri, S. J., Das, N. K., Chakraborty, B., Chatterjee, U., & Chatterjee, M. (2026). Immune-mediated remodelling of tissue architecture in Post-Kala-Azar Dermal Leishmaniasis (PKDL). PLOS Neglected Tropical Diseases, 20(10), e0014798. https://doi.org/10.1371/journal.pntd.0014798

Image Credits: AI Generated

DOI: 10.1371/journal.pntd.0014798

Keywords: PKDL, visceral leishmaniasis, hypopigmentation, E-cadherin, MMP9, chemokines, extracellular matrix, macrophages, CD8 T cells, TNF-alpha, IFN-gamma, skin pathology

The finding is significant because IgE sits at the very center of the allergic cascade. Allergen-specific IgE is produced exclusively by B cells, and upon re-exposure to an allergen such as house dust mite, these antibodies arm mast cells and basophils, triggering their degranulation and the clinical symptoms of asthma. At the same time, T helper 2 cells recruited to the airways secrete IL-4, IL-5 and IL-13, cytokines that promote local IgE production, eosinophil accumulation, airway hyperresponsiveness and mucus hypersecretion. While the extracellular signals that push B cells toward IgE have been studied extensively, the intrinsic molecular machinery inside B cells that governs this process has remained poorly defined, which is precisely the gap the new work addresses.

The researchers began by asking whether Ssu72 responds to the signals that activate B cells during allergic reactions. In cultured mouse B cells, Ssu72 protein and mRNA levels rose markedly after stimulation with anti-CD40, an antibody that mimics the T cell help B cells receive through CD40 ligation, as well as after combined anti-IgM and anti-CD40 stimulation and exposure to the T helper 2 cytokine IL-4. Crucially, the pattern held in vivo: in a low-dose house dust mite model of allergic asthma, B cells from the spleens of asthmatic mice showed significantly elevated Ssu72 compared with controls, and immunofluorescence imaging revealed heightened Ssu72 expression in B220-positive B cells infiltrating the inflamed lungs. The enzyme, in other words, is switched on exactly where and when the allergic response is being built.

To test whether this upregulation matters functionally, the team generated mice lacking Ssu72 only in B cells by crossing Ssu72-floxed animals with CD19-Cre mice, producing what they call Ssu72-BKO mice. Importantly, baseline B cell development appeared largely intact: total splenic B cell numbers were comparable to wild-type littermates, and with careful gating the major follicular, transitional and marginal zone subsets were unchanged. The knockout mice also mounted normal antigen-specific IgM and IgG responses after immunization with T cell-dependent and T cell-independent antigens, formed normal germinal centers and generated normal plasma cell populations. Ssu72, it seems, is dispensable for general antibody immunity but becomes critical in the specific context of allergic, T helper 2-driven inflammation.

That context-dependence showed itself clearly in the asthma model. After sensitization and challenge with house dust mite extract, Ssu72-BKO mice had visibly less peribronchial and perivascular inflammation on histology, lower inflammation scores, and significantly fewer total cells, eosinophils, T cells and B cells in bronchoalveolar lavage fluid. Immunohistochemistry for B220 and eosinophil cationic protein confirmed reduced B cell and eosinophil infiltration in lung tissue. Most strikingly, serum levels of total and house dust mite-specific IgE and IgG1 were substantially lower in the knockout animals, while HDM-specific IgM, IgG2b and IgG3 were unaffected, indicating that B cell Ssu72 preferentially supports the IgG1 and IgE arms of the allergic antibody response.

Flow cytometry of the mediastinal lymph nodes revealed why. Class switching to IgG1 and IgE normally occurs in germinal centers with help from T follicular helper cells, and in Ssu72-BKO mice both the percentage and number of IgG1-positive B cells, germinal center B cells and T follicular helper cells were significantly reduced after asthma induction. The defect was also cell-intrinsic: when purified B cells from knockout and wild-type mice were stimulated in vitro with LPS plus IL-4, the Ssu72-deficient cells showed markedly fewer IgG1-positive cells at days three and six, fewer intracellular IgE-positive cells at day six, and lower secreted IgG1 and IgE, while IgM production was unaffected. The knockout B cells also proliferated less, expressed less Ki67, survived less well by Annexin V and propidium iodide staining, and showed blunted early activation markers CD69 and CD86.

The study also uncovered a second, mechanistically distinct route by which Ssu72 shapes IgE: the regulation of CD23, the low-affinity IgE receptor. Membrane-bound CD23 on B cells normally restrains IgE synthesis, whereas its cleaved soluble form, sCD23, enhances it. Ssu72-BKO mice produced significantly less sCD23 during house dust mite asthma while retaining higher levels of membrane CD23 on their lymph node B cells. The team traced this to reduced induction of ADAM10, the established sheddase that clips CD23 from the cell surface, and reduced expression of MMP9, a matrix metalloproteinase previously implicated in LPS-driven CD23 cleavage. Consistent with a conserved mechanism, an analysis of public RNA sequencing data from activated human B cells revealed a positive correlation between Ssu72 and MMP9 expression, suggesting the pathway may operate in human allergy as well.

Delving deeper into signaling, the researchers found that Ssu72-deficient B cells had reduced phosphorylation of S6K and S6, canonical readouts of mTORC1 activity, alongside sharply increased phosphorylation of AMPKα at Thr172, the activating modification of the cellular energy sensor AMPK. Because AMPK negatively regulates mTORC1, and mTORC1 drives the protein synthesis and anabolic growth that class-switched B cells need to proliferate and secrete antibody, this imbalance offers a coherent explanation for the defective IgG1 and IgE responses. Co-immunoprecipitation experiments in transfected HEK293T cells and in the human Ramos B cell line demonstrated a physical interaction between Ssu72 and AMPKα, raising the possibility that Ssu72 directly dephosphorylates AMPKα, although the authors note that direct phosphatase assays and catalytically inactive Ssu72 mutants will be needed to confirm AMPKα as a true substrate.

Perhaps the most clinically suggestive result came from adoptive transfer experiments. When B cells from wild-type or Ssu72-deficient donors were transferred into B cell-deficient μMT mice that had already been sensitized to house dust mite, and the recipients were then challenged, the mice receiving Ssu72-deficient B cells developed less lung inflammation, fewer airway eosinophils, T cells and B cells, and lower serum IgE. This shows that Ssu72 matters not only during the sensitization phase, when IgE-switched B cells are generated, but also during the effector phase, when re-exposure to allergen triggers disease. The knockout B cells additionally displayed reduced MHC class II upregulation in lymph nodes and lungs, and the mice showed fewer IL-4- and IL-13-producing CD4-positive T cells in both compartments, along with lower IL-4 in bronchoalveolar lavage fluid and serum, implying that Ssu72-expressing B cells help sustain the T helper 2 dialogue through antigen presentation.

Taken together, the study positions Ssu72 as a context-dependent, B cell-intrinsic checkpoint that licenses class switching to IgG1 and IgE, promotes CD23 shedding through ADAM10 and MMP9, and tunes the AMPK-mTORC1 metabolic axis. Because general humoral immunity was preserved in the knockout mice, the authors argue that selectively targeting Ssu72 in B cells could dampen allergic airway inflammation without broadly compromising the antibody defenses a patient needs against infection. Much remains to be worked out, including how Ssu72 controls ADAM10 and MMP9 expression and how the AMPK and CD23-shedding pathways intersect. But for a disease in which IgE remains a prime therapeutic target, an intracellular enzyme that quietly orchestrates its production offers an enticing new lead, and one that the field will now be eager to pursue from mouse airways toward human clinics.

Subject of Research: The role of the B cell-intrinsic phosphatase Ssu72 in regulating IgE production and allergic airway inflammation

Article Title: B cell-intrinsic Ssu72 phosphatase is a key regulator of allergic asthma

Article References: Koo, S.-Y., Wang, N., Kim, M.-H., Lee, S., Kim, T. J., & Lee, C.-W. (2026). B cell-intrinsic Ssu72 phosphatase is a key regulator of allergic asthma. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01859-0

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01859-0

Keywords: Ssu72 phosphatase, B cells, allergic asthma, IgE, class switch recombination, CD23 shedding, ADAM10, MMP9, AMPK, mTORC1, T helper 2 cytokines, house dust mite

The study, published in Cellular and Molecular Life Sciences, tested empagliflozin, a sodium-glucose cotransporter 2 inhibitor, in a well-established animal model of aneurysm disease. Male ApoE-deficient mice, which are highly susceptible to vascular pathology, were infused with angiotensin II to trigger abdominal aortic aneurysm formation. One group of animals received the drug at a dose of 3 milligrams per kilogram per day for 28 days. The differences at the end of the study were striking. Among the aneurysm animals, 73.3 percent developed the disease; among those treated with empagliflozin, only 26.6 percent did. Maximum aortic diameter was significantly reduced, aortic rupture became far less common, and survival improved from 73.3 percent to 86.7 percent, a difference the authors report as statistically significant.

Abdominal aortic aneurysm is a permanent, irreversible dilation of the aorta that grows silently over years and can rupture without warning. Rupture carries mortality rates that exceed 80 percent in many settings, and because no drug is currently approved to slow or prevent the disease, the only definitive treatment is surgical repair, typically once the vessel exceeds a critical diameter. The search for a medical therapy has been one of the most persistent unmet needs in vascular medicine, which is why the idea that a glucose-lowering agent might double as an aneurysm-protective drug has generated considerable interest.

What makes the new findings remarkable is not only the magnitude of protection but the mechanism the investigators uncovered. Empagliflozin was already known to deliver cardiovascular benefits beyond its glucose-lowering effects, but this study is among the first to show that its protective activity in aneurysm disease depends on the gut microbiome. When the researchers depleted the animals’ gut bacteria with antibiotics, the drug lost virtually all of its aneurysm-fighting power. Conversely, when they transplanted fecal microbes from empagliflozin-treated mice into untreated animals, the recipients gained the drug’s benefits, showing reduced aneurysm incidence, diminished vascular inflammation, and stronger intestinal barriers. In effect, the microbiome was both necessary and sufficient to transfer the protection.

To understand how a diabetes drug reshapes microbial communities, the team performed 16S rRNA sequencing on fecal samples from each experimental group. The sequencing revealed a clear restructuring of the gut ecosystem. At the phylum level, empagliflozin increased the abundance of Tenericutes, a lesser-known bacterial lineage. At the genus level, the drug enriched several taxa, including Sutterella, Allobaculum, Colinsella, and Pelomonas, while reducing Methylobacterium. Functional prediction analysis using PICRUSt2 suggested shifts in microbial metabolic pathways, indicating that the drug’s influence extended beyond simple taxonomic changes to the biochemical work performed by the community as a whole.

Metabolic readouts confirmed those structural shifts. Targeted liquid chromatography coupled to tandem mass spectrometry showed empagliflozin-associated changes in fecal short-chain fatty acids, the beneficial microbial metabolites that nourish the gut lining and dampen systemic inflammation, as well as changes in plasma trimethylamine N-oxide, a metabolite produced by gut bacteria that has been repeatedly linked to cardiovascular disease. The drug simultaneously raised protective metabolites and lowered harmful ones, tilting the gut’s chemical output in a direction associated with vascular health.

The vascular consequences were equally measurable. In the aortic tissue of aneurysm animals, empagliflozin reduced the infiltration of inflammatory cells, preserved the integrity of elastic fibers in the vessel’s medial layer, and suppressed the angiotensin II-driven upregulation of matrix metalloproteinases, the tissue-destroying enzymes that digest the aortic wall. Levels of MMP9 and MMP2, both central players in aneurysm development, were significantly lower in treated animals. These enzymes are the molecular scissors that progressively weaken the artery; restraining them is widely considered the key pharmacological goal in aneurysm research.

The gut side of the story proved just as important. Aneurysm-inducing angiotensin II damages the intestinal barrier, allowing bacterial products such as lipopolysaccharide to leak into the bloodstream and inflame distant organs, including the aorta. Empagliflozin reversed this damage. Treated mice showed restored intestinal villus structure, upregulated expression of the tight-junction proteins ZO-1 and Occludin at both the mRNA and protein levels, reduced intestinal permeability, and markedly lower plasma lipopolysaccharide concentrations. Downstream in the aortic wall, the drug attenuated TLR4/NF-κB signaling, the classical inflammatory pathway activated by bacterial products that drives the chronic inflammation underlying aneurysm growth.

Assembled together, the evidence outlines a coherent biological circuit. Empagliflozin reshapes the gut microbiota, enriching beneficial taxa and shifting metabolite production toward short-chain fatty acids. Those changes restore the integrity of the intestinal barrier, preventing bacterial toxins from crossing into the circulation. With fewer circulating toxins, TLR4/NF-κB inflammation in the aortic wall subsides, destructive metalloproteinases are restrained, elastic fibers survive, and the artery remains structurally sound. The antibiotic depletion and fecal transplantation experiments serve as the causal linchpins of this model, demonstrating that the gut microbial community is the mediator through which the drug exerts its vascular protection rather than an incidental bystander.

The findings carry implications that extend well beyond aneurysm research. They suggest that some of the cardiovascular benefits of SGLT-2 inhibitors, a drug class already credited with unexpected heart and kidney protection in large clinical trials, may be mediated in part through the gut. They also point toward microbiome-based strategies for aneurysm prevention, whether through drugs, diet, or microbial therapies, in a disease where medicine currently offers nothing between surveillance and surgery. The authors are careful to frame the work as experimental: the results come from mice given angiotensin II, and human aneurysms develop over decades in a very different physiological context. Clinical trials in patients will be needed to determine whether empagliflozin, or the microbial signatures it promotes, can slow aneurysm growth in people. Still, the study provides a novel preventive strategy and a clear mechanistic target, the gut microbiota and intestinal barrier axis, for a disease that has lacked one. For the millions of patients carrying small, silently enlarging aneurysms, the possibility that a widely available drug might one day stop the growth is a prospect worth watching closely, and the gut, once again, sits at the center of the story.

Subject of Research: Gut microbiome-mediated protective effects of the SGLT-2 inhibitor empagliflozin against experimental abdominal aortic aneurysm formation and progression

Article Title: Gut microbiome mediates the protective effects of empagliflozin on experimental abdominal aortic aneurysm formation and progression

Article References: Guo, W., Hu, H., Wang, S., Li, D., Li, C., Chen, X., Deng, D., Xiao, J., Shen, Y., & Wei, Z. (2026). Gut microbiome mediates the protective effects of empagliflozin on experimental abdominal aortic aneurysm formation and progression. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06449-x

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06449-x

Keywords: abdominal aortic aneurysm, empagliflozin, SGLT-2 inhibitor, gut microbiota, intestinal barrier, inflammation, 16S rRNA sequencing, short-chain fatty acids, TMAO, TLR4/NF-κB signaling, MMP9, fecal microbiota transplantation

The scale of the problem they targeted is enormous. More than nine million osteoporotic fractures occur worldwide each year, and people living with diabetes mellitus face a 20 to 50 percent higher risk of fragility fractures than the general population. Diabetic osteoporosis is increasingly described as a dual pandemic, driven by mechanisms that differ fundamentally from ordinary age-related bone loss. Advanced glycation end products, insulin resistance, oxidative stress, and elevated inflammatory cytokines all conspire to disrupt bone metabolism, lowering osteoprotegerin while raising RANKL, a signal that fuels osteoclast-driven bone resorption. At the same time, chronic inflammation and hyperglycemia push bone-forming osteoblasts toward apoptosis and steer mesenchymal stem cells away from bone formation and toward fat production, a molecular switch governed by activated PPAR-gamma and suppressed Runx-2 expression.

Because existing antidiabetic drugs manage blood glucose imperfectly and carry side effects without curing the underlying disease, the research team turned to bioinformatics to hunt for multi-target natural molecules. Their strategy began with predicting genistein’s pharmacokinetic profile using the SwissADME web tool and its oral toxicity using ProTox-II and ProTox-3.0, which returned encouraging drug-likeness scores and low predicted toxicity. They then mined the GeneCards and Comparative Toxicogenomic databases for disease targets, retrieving a staggering 32,133 genes associated with diabetes mellitus and osteoporosis, and used Swiss Target Prediction to identify 105 human protein targets for genistein itself.

Overlaying the two gene sets produced a protein-protein interaction network of 104 nodes and 606 edges, visualized in Cytoscape and analyzed through topological parameters including degree, betweenness centrality, and closeness centrality. Five hub genes rose decisively above the rest: EGFR, the epidermal growth factor receptor; ESR1, the estrogen receptor alpha; MMP9, matrix metalloproteinase-9; PTGS2, the inflammatory cyclooxygenase-2 enzyme; and PPARG, the nuclear receptor governing fat and glucose metabolism. Gene ontology and KEGG pathway enrichment analyses revealed that these targets converge on the PPAR signaling pathway and EGFR tyrosine kinase inhibitor resistance pathways, alongside biological processes spanning apoptosis regulation, stress response, growth factor signaling, and catecholamine metabolism.

The computational deep-dive then moved to the atomic scale. Molecular docking using Schrödinger’s Glide module showed genistein binding strongly to all four top targets, with the strongest standard-precision score of minus 10.752 kcal/mol against ESR1, followed by minus 8.381 against EGFR, minus 7.096 against MMP9, and minus 6.495 against PPARG. Each complex was anchored by specific hydrogen bonds and hydrophobic contacts within the binding pockets, indicating that the soy isoflavone nestles into the same active regions as purpose-built synthetic drugs.

Docking, however, captures only a frozen snapshot. To test whether these interactions survive the thermal chaos of a living cell, the team ran 100-nanosecond molecular dynamics simulations in triplicate for each protein-ligand complex using the Desmond engine at 300 Kelvin under constant pressure and temperature. All four systems equilibrated within 20 nanoseconds and remained stable throughout. Backbone root-mean-square deviations stayed between 1.8 and 2.5 angstroms, ligand RMSD values remained below 2 angstroms, and active-site residues fluctuated less than 1.5 angstroms. The ESR1 and PPARG complexes proved especially robust, maintaining three to four hydrogen bonds for roughly 80 to 88 percent of the trajectory and retaining high alpha-helical content of about 55 to 57 percent, signatures of thermodynamically stable, persistent binding.

MM/GBSA free energy calculations sealed the computational case. The ESR1 complex posted the most favorable binding free energy at minus 51.86 kcal/mol, followed by EGFR at minus 49.23 and PPARG at minus 42.82, with van der Waals, electrostatic, and nonpolar solvation terms driving the favorable energetics. These numbers confirmed that genistein’s grip on its targets is not an artifact of rigid-receptor scoring but a genuinely stable molecular partnership sustained by the same forces that govern real drug binding.

Crucially, the researchers did not stop at the computer. In a dexamethasone-induced insulin resistance rat model, a well-established experimental mimic of type 2 diabetes metabolic dysfunction, genistein was formulated as a solid dispersion with PVP-K30 to improve solubility and administered orally at 1, 2, and 4 mg/kg daily for 25 days. Post-treatment, genistein-treated rats showed statistically significant reductions in fasting blood glucose and serum insulin compared with untreated positive controls, with the highest dose performing best, indicating restored insulin sensitivity.

The skeletal results were equally compelling. Scanning electron microscopy of rat femurs revealed that diabetic control animals had porous, microcracked, eroded trabecular surfaces and visible resorption pits, while genistein-treated bones appeared dense, compact, and structurally organized. Nanoindentation showed that treated animals maintained tissue-level hardness and reduced modulus close to normal values, and three-point bending tests demonstrated dramatic mechanical recovery: maximum load capacity in the highest-dose group reached 67.4 newtons, exceeding even the normal control value of 60.81 newtons, while the untreated diabetic group collapsed to just 10.33 newtons. Ultimate stress, stiffness, and toughness all followed the same restorative pattern.

Mechanistically, the findings weave a coherent story. EGFR dysregulation impairs the PI3K/AKT insulin signaling axis and undermines osteoblast survival, while genistein’s selective affinity for estrogen receptor beta and modulation of NF-kB and MAPK pathways counteracts inflammation-driven bone resorption. MMP9, overexpressed under hyperglycemic oxidative stress, chews through bone matrix and is partially responsible for skeletal degradation in diabetic animals, and PPAR-gamma overactivation diverts bone marrow stem cells into fat rather than bone. By binding all of these targets simultaneously, genistein appears to act as a dual-action agent, lowering blood glucose while defending bone microarchitecture and mechanical strength. The authors caution that further clinical and translational work is needed, but their integrated evidence positions this inexpensive soy-derived phytoestrogen as a promising template for evidence-based functional foods and tailored therapeutics against a complication that diabetes medicine has long undermanaged.

Subject of Research: Genistein as a multi-target phytoestrogen therapy for diabetic osteoporosis, investigated through network pharmacology, molecular docking, molecular dynamics simulation, and rat model experiments

Article Title: Genistein potential and mechanisms against diabetes osteoporosis: An integrated study of network pharmacology, molecular docking, and molecular dynamics simulation

Article References: Sharma, S., Chaudhary, R., Hooda, T., Sharma, C., Dabral, S., Kumar, A., Bansal, S., & Gupta, S. (2026). Genistein potential and mechanisms against diabetes osteoporosis: An integrated study of network pharmacology, molecular docking, and molecular dynamics simulation. Results in Chemistry, 30, Article 103833. https://doi.org/10.1016/j.rechem.2026.103833

Image Credits: AI Generated

DOI: 10.1016/j.rechem.2026.103833

Keywords: genistein, diabetic osteoporosis, network pharmacology, molecular docking, molecular dynamics simulation, MM/GBSA, EGFR, ESR1, MMP9, PPARG, insulin resistance, bone metabolism